PROCEPT BioRobotics (NASDAQ:PRCT) is a medical technology company specializing in robotically enabled solutions for urological applications. The company’s flagship product, the AquaBeam® Robotic System, employs high-velocity waterjet technology to perform minimally invasive treatment of benign prostatic hyperplasia (BPH). Designed to enhance precision and consistency, AquaBeam offers a targeted approach that preserves healthy tissue while reducing procedure times and facilitating quicker patient recovery compared to traditional surgical methods.
In addition to its therapeutic platform, PROCEPT BioRobotics has developed the HERO® System, which integrates robotic assistance and advanced imaging for targeted prostate mapping and biopsy. By combining spatial localization with automated needle guidance, the HERO System aims to improve diagnostic accuracy for prostate cancer while minimizing patient discomfort and procedural variability. Together, these offerings reflect the company’s focus on leveraging robotics to address unmet needs in urology.
Founded in 2009 and headquartered in Redwood City, California, PROCEPT BioRobotics has expanded its footprint across North America, Europe and select international markets. The company holds multiple regulatory approvals, including FDA clearance and CE Mark certification, enabling its platforms to be adopted by leading hospitals and outpatient centers worldwide. PROCEPT continues to invest in clinical research, partnering with academic institutions to generate evidence on the safety, efficacy and cost-effectiveness of its technologies.
Under the leadership of President and CEO Elliot V. Bothell, PROCEPT BioRobotics has grown its commercial and clinical teams to support ongoing product innovation and market expansion. The management team includes seasoned professionals with backgrounds in medical devices, robotics and healthcare operations. As PROCEPT builds on its initial milestones, it remains committed to advancing patient care through precision robotics and data-driven solutions in urology.